Managing Chronic Kidney Disease (CKD)
in Type 2 Diabetes
Focus on MRAs — Expert insights from our multidisciplinary, pan-Canadian panel on screening, guidelines, residual risk, and novel treatments
About This Program
Hear what our multidisciplinary, pan-Canadian expert panel has to say about chronic kidney disease (CKD) in patients with type 2 diabetes (T2D) in the Hallway Huddle. Each 5–10-minute video in this series features one of our experts presenting the latest on screening, guidelines, residual risk, and novel treatments for the management of CKD in T2D.
French Version AvailableLearning Objectives
1
Apply guideline-based screening for CKD in patients with T2D
2
Address residual risk in patients with CKD and T2D beyond current therapies
3
Implement disease-modifying therapies in patients with T2D and CKD
4
Safely manage potential adverse events, such as hyperkalemia
5
Apply updated Diabetes Canada guidelines to the management of patients with CKD and T2D
6
Assess albuminuria and GFR when evaluating cardiorenal risk
7
Describe mechanisms of action of new therapies and their complementarity
8
Counsel patients on rationale for adding therapies to current regimens
9
Initiate and monitor finerenone in a timely and safe manner
Access Program Content
Choose how you'd like to explore CKD management in T2D — watch expert videos or ask our AI assistant
Ask Our AI Assistant
Get instant, personalized answers about CKD management, MRA therapy, and guideline recommendations. Our AI assistant is trained on all program content including expert videos and clinical guidelines.
Expert Video Library
Browse our collection of expert presentations on key topics
1
When and why should patients with T2D have their UACR tested?
Navdeep Tangri, MD, PhD, FRCPC
2
What do the guidelines say about managing CKD in T2D?
Alice Y.Y. Cheng, MD, FRCPC
3
What are the key differences between steroidal MRAs and nonsteroidal MRAs?
Daniel Ngui, BScPT, PT, MD, CCFP, FCFP
4
For which patients should novel nonsteroidal MRAs be considered?
Normand Proulx, MD, FRCP(C)
5
What data supports the use of novel nonsteroidal MRAs in patients already on an SGLT2 inhibitor?
Normand Proulx, MD, FRCP(C)
6
When and how should potassium levels be monitored and managed in patients on MRAs?
Louise Moist, MD, MSc, CCPE, FRCPC
7
What is residual risk and why does it matter in patients with CKD and T2D?
Navdeep Tangri, MD, PhD, FRCPC
8
Measures of albuminuria and why UACR is the gold standard for measuring cardiorenal risk
Jordan Weinstein, MD, FRCPC
9
What are the MOAs of the new therapies and how do they complement each other?
Normand Proulx, MD, FRCP(C)
10
What to know about initiating and monitoring patients on finerenone?
Jordan Weinstein, MD, FRCPC
11
What to tell patients about adding another treatment, like finerenone to their regimen?
Shelley Zieroth, MD, FCCS, FHFSA (hon), FESC, FACC, FHFA, FRCPC
12
What are the highlights from the 2025 Diabetes Canada CKD in Diabetes Guidelines? NEW
Philip McFarlane, MD, FRCPC, PhD & Sara Stafford, MDCM, FRCPC
Expert Faculty
Our multidisciplinary panel of Canadian healthcare professionals
Alice Y.Y. Cheng
MD, FRCPC
Endocrinologist, Trillium Health Partners & Unity Health Toronto
Associate Professor, University of Toronto
Toronto, ON
Associate Professor, University of Toronto
Toronto, ON
Claude Garceau
M.D., FRCP Interniste, IUCPQ
Internist, IUCPQ
Université Laval
Member of the National Diabetes Trajectory Committee
Member of the National Obesity Trajectory Committee
Lecturer, IPSA UL Medical Education
Québec, QC
Université Laval
Member of the National Diabetes Trajectory Committee
Member of the National Obesity Trajectory Committee
Lecturer, IPSA UL Medical Education
Québec, QC
Louise Moist
MD, MSc, CCPE, FRCPC
Professor of Medicine Epidemiology and Biostatistics
Nephrologist, London Health Sciences Centre
Deputy Chair, Division of Nephrology
Schulich School of Medicine & Dentistry, Western University
London, ON
Nephrologist, London Health Sciences Centre
Deputy Chair, Division of Nephrology
Schulich School of Medicine & Dentistry, Western University
London, ON
Daniel Ngui
BSc, PT, MD, CCFP, FCFP
Clinical Professor, Department of Family Medicine
University of British Columbia
Medical Director, Fraser Street Medical
Vancouver, BC
University of British Columbia
Medical Director, Fraser Street Medical
Vancouver, BC
Normand Proulx
MD, FRCP(C)
Nephrologist, CISSS de l'Outaouais
Pavillon de Hull
Part-time Lecturer, McGill University
Gatineau, QC
Pavillon de Hull
Part-time Lecturer, McGill University
Gatineau, QC
Sara Stafford
MDCM, FRCPC
Nephrologist
Assistant Professor, McGill University
Montreal, QC
Assistant Professor, McGill University
Montreal, QC
Navdeep Tangri
MD, PhD, FRCPC
Attending physician and Associate Professor, Division of Nephrology,
Department of Medicine and the Department of Community Health Sciences, University of Manitoba
Scientific Director, Chronic Disease Innovation Centre at Seven Oaks General Hospital
Winnipeg, MB
Department of Medicine and the Department of Community Health Sciences, University of Manitoba
Scientific Director, Chronic Disease Innovation Centre at Seven Oaks General Hospital
Winnipeg, MB
Michael Tsoukas
MD
Investigator, RI-MUHC, Glen site
Metabolic Disorders and Complications Program
Associate Professor, Department of Medicine, McGill University
Division of Endocrinology and Metabolism, MUHC
Montreal, QC
Metabolic Disorders and Complications Program
Associate Professor, Department of Medicine, McGill University
Division of Endocrinology and Metabolism, MUHC
Montreal, QC
Jordan Weinstein
MD, FRCPC
Nephrologist
Assistant Professor, University of Toronto
Toronto, ON
Assistant Professor, University of Toronto
Toronto, ON
Shelley Zieroth
MD, FCCS, FHFSA (hon), FESC, FACC, FHFA, FRCPC
Cardiologist
Professor of Medicine, University of Manitoba
Winnipeg, MB
Professor of Medicine, University of Manitoba
Winnipeg, MB
Philip McFarlane
MD, FRCPC, PhD
Nephrologist
Associate Professor, University of Toronto
Toronto, ON
Associate Professor, University of Toronto
Toronto, ON
